White Coat Hypertension: The Role of Anxiety, Stress, and Emotional Reactivity in Blood Pressure Elevation

White coat hypertension (WCH) was first formally described in the medical literature during the 1980s, characterized by consistently elevated blood pressure readings in a clinical setting when measured by a healthcare professional, while remaining within the normal range when assessed outside the medical environment using ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) ^[1,2]. The phrase "white coat" refers to the usual clothing that doctors wear, which suggests that the actual visit to a doctor — along with the feelings and emotions that come with it — can temporarily raise blood pressure^[3]. The percentage of people who have WCH and are being checked for high blood pressure is between 15% and 30%, but this number can change based on the rules used to diagnose WCH and how it is measured ^[4,5]. Current international guidelines, like the ones from the European Society of Hypertension (ESH 2023) and the American College of Cardiology/American Heart Association (ACC/AHA 2017), say that White Coat Hypertension (WCH) is when blood pressure is 140/90 mmHg or higher in a clinic setting, but the average blood pressure during the day, measured continuously, is below 135/85 mmHg ^{[6, 7]}. The condition has historically been seen as relatively harmless; however, growing evidence suggests that WCH is associated with increased cardiovascular risk compared to true norm tension, especially in untreated individuals ^{[8, 9]}. Over the last twenty years, the mental health aspects of WHC- including anxiety, stress related to social and psychological factors, and depression – have become a bigger focus of research. Many patients find medical visits stressful and worrying, especially when they are worried about getting a hypertension diagnosis. The power dynamic between a patient and a doctor can make this situation even tenser, leading to a strong physical reaction that affects the body’s blood pressure and circulation ^{[10, 11]}. This review thoroughly investigates the psychological mechanisms behind WHC, the two-way connections between WHC, and mood disorders, and the consequences for diagnosis, prognosis, and treatment.

Definition and Diagnostic Methods

Defining White Coat Hypertension: WHC happens when someone has high blood pressure in the office but normal blood pressure when they are not at work. The most widely accepted definition requires a systolic BP of ≥140 mmHg and/or diastolic BP ≥ 90mmHg, alongside a mean 24-hour ambulatory BP below 130/80 mmHg or a mean daytime ambulatory BP below 135/85 mmHg ^{[6, 12]}. Another similar but separate things is called the ‘white coat effect’ (WCE). It means there is a difference in blood pressure readings taken in a doctor’s office compared to those taken at home or other and this difference happens even if the actual numbers do not reach certain high levels. WCE can happen in people who have normal blood pressure and I those who already have long-term high blood pressure (SH) ^[13]. In some people with high blood pressure who are being treated, their blood pressure stays high during doctor visits even though their overall blood pressure has gone down when measured throughout the day. This situation is called 'white coat uncontrolled hypertension' (WUCH) ^[14]. According to the 2023 ESH Guidelines, about 10 to 15% of people with high blood pressure who are being treated have WUCH, and this condition can be mistaken for treatment resistance, which might cause doctors to increase the amount of blood pressure medicine they give ^[7].

Diagnostic Methods

The best way to diagnose WCH is through 24-hour ambulatory blood pressure monitoring (ABPM), which records blood pressure changes throughout the day and night ^[15]. ABPM is set up to measure blood pressure every 15 to 30 minutes during the day and every 30 to 60 minutes at night, giving a full picture of how blood pressure changes throughout the day. This method avoids the effect that happens when blood pressure is checked during a medical visit ^[16]. Home blood pressure monitoring helps in checking blood pressure at home, but it is not as good as ambulatory blood pressure monitoring at finding white coat hypertension. It is better at correctly identifying people who do not have high blood pressure ^[17]. Both the 2023 ESH and 2024 ESC guidelines strongly suggest measuring blood pressure outside the office to confirm the diagnosis of WCH ^{[18, 19]}. The importance of the diagnostic process on a psychological level should not be ignored. Patients who believe they have hypertension show higher anxiety levels during clinical blood pressure measurements and experience a more pronounced white coat effect compared to normotensive individuals who are unaware of their blood pressure status, regardless of their actual blood pressure levels ^[20].

Pathophysiology: Neurobiological and Psychological Mechanisms

The Alerting Response and Sympathetic Activation: The basic way WCH works is through the alerting response — a type of nervous system reaction that happens because of the hospital setting, the presence of a healthcare worker, or the worry about a bad health problem ^[21]. This response triggers the sympathetic nervous system, which causes the body to release catecholamine, increases the heart's pumping strength, raises resistance in blood vessels, and leads to a temporary rise in blood pressure ^[22]. Studies have shown significant activation of skin sympathetic nerve activity and inhibition of muscle nerve traffic when physicians were present during blood pressure measurement, a pattern similar to the 'defence reaction' seen in animal models under emotional stress ^[10]. Evidence from the PAMELA (Pressioni Arteriose Monitorate e Loro Associazioni) cohort study shows that WCH is associated with increased peripheral sympathetic nerve activity, comparable to that seen in sustained hypertension, implying a neurogenic origin with potential prognostic significance ^[23]. Research on heart rate variability (HRV) in people with WCH has shown that their hearts are less controlled by the parasympathetic nervous system. This is seen in lower high-frequency power and higher LF/HF ratios compared to people without high blood pressure, which suggests that their autonomic nervous system is not working properly ^[24].

Role of Anxiety in WCH: Anxiety is the most extensively studied psychological correlate of WCH. Patients with WCH show more anxiety than both people with normal blood pressure and those with long-term high blood pressure. This was measured using tools like the Hospital Anxiety and Depression Scale (HADS), State-Trait Anxiety Inventory (STAI), and Beck Anxiety Inventory (BAI) ^{[25, 26]}. A 2024 study in Turkey looked at 303 patients and used the HADS-Anxiety part of a test. They found that people with higher anxiety scores were more likely to have WCH, even after considering other factors. Patients with WCH had noticeably higher anxiety levels than those who had long-term high blood pressure ^[25]. The feeling of thinking you have high blood pressure can make you more anxious, which makes the white coat effect worse. People, who think they have high blood pressure, even if their real blood pressure is not high, feel more nervous before going to the doctor. This nervousness actually causes their blood pressure to go up during the visit ^[20]. Two explanatory models have been proposed: (1) the 'sick role' hypothesis, in which patients diagnosed with hypertension exhibit illness-consistent behaviours and unconsciously raise their blood pressure through anxiety during clinical interactions; and (2) the 'negative anticipation' model, where the expectation of receiving bad health news increases anxiety and blood pressure reactivity^[11]. However, the relationship between anxiety and WCH is not uniformly straightforward. Some studies did not find clear differences in anxiety levels between WCH and non-WCH groups when using standard tools to measure anxiety, which suggests that WCH might not just be about a person's usual anxiety level. Instead, it seems that factors related to the situation and the clinical setting play a bigger role than someone's usual personality traits ^{[27, 28]}. How anxiety interacts with whether someone is taking antihypertensive medication changes this connection: for people who are on treatment, higher anxiety is linked to a bigger chance of the white coat effect, but for those not on treatments, this link is weaker ^[29].

Psychological Stress and WCH: Chronic psychosocial stress plays a key role in the development of both WCH and long-term high blood pressure. Stress activates the hypothalamic-pituitary-adrenal (HPA) axis, leading to the release of cortisol, which subsequently promotes sodium retention, increases peripheral vascular resistance, and enhances vascular reactivity to catecholamine’s ^[30]. At the same time, when the SNS is constantly active, it leads to higher levels of adrenaline and noradrenaline in the blood, which makes blood vessels constrict more and increases blood pressure fluctuations ^[31]. In patients with WCH, the way blood pressure responds to mental stress tasks like doing math problems, speaking in front of people and reaction time tests is linked to how strong the white coat effect is in people with high blood pressure, but this connection is not seen in people with normal blood pressure ^[32]. High levels of stress, especially in women, seem to connect more strongly with WCH compared to men, showing that how affects people stress might differ between sexes. This could explain why WCH is more common in women ^[33]. Work-related stress, pressure from jobs, and stress from the social and surrounding environment are extra factors that can affect blood pressure changes and keep the white coat effect going ^[34].

Depression, Neurohumoral Pathways, and Blood Pressure: Depression, though not directly implicated in WCH, exerts significant modulatory effects on BP regulation and cardiovascular risk through overlapping biological pathways. Depression is linked to problems with the HPA axis, higher levels of inflammation-causing chemicals like interleukin-6 and TNF-alpha, and a weaker bar reflex response — all of which together affect the body's ability to control blood pressure properly ^[35,36]. A meta-analysis of prospective studies showed a significant link between depression and the risk of developing hypertension, with an odds ratio of around 1.20 and a hazard ratio of 1.28, suggesting a causal relationship ^[37]. The idea of vascular depression suggests that there is a two-way connection between high blood pressure and depression. High blood pressure can cause changes in the blood vessels of the brain, like small vessel disease and less blood flow to the brain, which might make someone more likely to develop depression by affecting the brain areas that control mood. At the same time, depression can lead to changes in the body's hormones and inflammation, which can speed up problems with blood vessels and make it harder to control blood pressure ^[38]. In hypertensive patients, depression has been associated with poorer blood pressure control, lower medication adherence, and unhealthy lifestyle behaviours such as reduced physical activity, increased alcohol consumption, and poor dietary habits, which further exacerbate cardiovascular risk ^[39].

Personality Traits, Neuroticism, and WCH: Personality traits have been studied as possible factors that influence how likely someone is to experience WCH. Patients with WCH have been described as demonstrating a tendency to suppress emotions and exhibit over-adaptive behavioural patterns, with elevated 'adapted child' scores on ego-state measures compared to those with sustained hypertension ^[40]. Neuroticism, which is a personality trait where someone often feels bad emotions like worry and sadness, has been linked in a complicated way to the white coat effect. In patients who take medicine for high blood pressure, people who feel more anxious (which is part of being nervous or worry-prone) tend to show a bigger white coat effect. This might mean they are more worried about whether their medicine is working or if their blood pressure is still too high ^[29]. Studies from future patient records show that certain personality features, like alexithymia and being introverted, might make some people more likely to have strong blood pressure reactions in medical situations ^[41].

Epidemiology, Prevalence, and Risk Factors

WCH is estimated to affect 15–30% of individuals referred for evaluation of elevated office BP, with higher prevalence in women, older adults (>50 years), and non-smokers ^{[42, 43]}. As people get older, this condition becomes more common. This is because older adults are more sensitive to feeling sick and their aortic walls become less flexible, which makes their blood pressure react more strongly to changes in how much blood the heart pumps during stress ^[3]. Geographic, ethnic, and socioeconomic factors also affect how common WCH is, with some studies showing that groups with lower health knowledge or more distrust in institutions have higher rates ^[44]. Anxiety disorders along with high blood pressure are very common in the United States and around the world. Systematic reviews suggest that anxiety and depression often co-occur in patients with hypertension, with depression prevalence in hypertensive populations ranging from 20% to over 50%, depending on the assessment method and study population ^[45]. Low-income populations experience greater burdens of comorbid hypertension, anxiety, and depression, primarily due to chronic stressors such as financial insecurity, housing instability, and limited access to mental health care ^[46]. A condition where depression and hypertension affect each other in both directions with depression leading to high blood pressure through inflammation and nervous system issues, and high blood pressure making mental health worse forms a cycle that makes it harder to diagnose and treat ^[47].

Cardiovascular Risk and Prognostic Implications

Previous studies pointed out that having white coat hypertension was not clearly linked to a higher risk of heart problems when compared to having normal blood pressure ^[48]. However, more studies that are recent have substantially revised this view. A 2019 review of 27 studies with 25,786 people who had white coat hypertension showed that not treating this condition was linked to a 36% higher chance of having a cardiovascular event (HR 1.36, 95% CI 1.03–2.00) and a 33% higher risk of dying from any cause (HR 1.33, 95% CI 1.07–1.67) ^[8]. These findings show how important it is to properly recognize and keep track of WCH patients instead of just giving them vague reassurance. The PAMELA study, which is one of the longest-running studies that follows people with high blood pressure over time, showed that WCH was linked to a higher chance of developing sustained hypertension, left ventricular hypertrophy and metabolic issues during a 10-year period ^[49]. The IDHOCO database found that people with white coat hypertension who were not being treated had a much higher risk of heart problems compared to those with normal blood pressure. The risk was about 42% higher, according to the study. However, people with white coat hypertension who were on medication did not show a higher risk, which might be because the treatment helped control their blood pressure ^[50]. The cardiovascular risk associated with WCH is partly due to increased blood pressure variability, sympathetic overdrive, and metabolic abnormalities, such as modestly elevated triglycerides, glucose, and creatinine, which commonly coexist in WCH patients ^[43]. Anxiety can trigger the body's stress response, leading to increased heart activity and higher levels of cortisol, which might over time damage blood vessels, make arteries less flexible, and boost inflammation, all of which can raise the risk of heart problems ^[35].

Clinical Assessment and Psychological Evaluation

To properly identify WCH, it is necessary to have accurate blood pressure readings taken with reliable equipment and a thorough psychological assessment. The ABPM is still the main tool for diagnosis, but HBPM is a helpful extra method that takes readings at home, where people are not stressed from being in a medical setting ^[17]. The Templer Death Anxiety Scale, HADS, State-Trait Anxiety Inventory, and Beck Depression Inventory are among the validated tools used in research to measure anxiety and depressive symptoms in WCH populations ^[26]. Patients who seem to have high blood pressure should undergo regular psychological checks, especially if their blood pressure readings are higher in a medical setting. A careful check for work-related stress, generalized anxiety disorder, panic disorder, or major depressive disorder might show psychological causes of high blood pressure that can be treated. The 2023 ESH Guidelines recognize the significance of behavioural and psychological factors in blood pressure measurement and management, whereas both the ACC/AHA 2017 guidelines and 2024 ESC guidelines highlight out-of-office monitoring as essential for an accurate diagnosis to identify and differentiate white coat hypertension from sustained hypertension ^{[7, 18, 19]}.

Management Strategies

Non-Pharmacological Approaches: Given the central role of anxiety, stress, and psychological reactivity in WCH, non-pharmacological interventions aimed at enhancing psychological well-being are fundamental to management. Relaxation techniques, mindfulness-based stress reduction (MBSR), biofeedback, cognitive behavioural therapy (CBT), and music therapy have all shown real, measurable improvements in blood pressure for people who have high blood pressure caused by stress or anxiety ^[34]. These methods help fix the problems in the HPA axis and autonomic nervous system that are linked to WCH, and in some studies, the benefits last even after the treatment has ended. Improving the relationship between patients and healthcare providers by using communication methods that focus on the patient's needs is another good non-drug treatment approach. Interventions such as waiting room relaxation programs, health educator coaching, and motivational interviewing to reduce pre-visit anxiety have been shown to mitigate the white coat effect ^[11]. Using telemedicine for blood pressure monitoring is a new approach that does not require a doctor's visit. It can remove the need for an alert system and offer better blood pressure readings to help doctors make more decisions that are informed. Lifestyle changes like doing regular aerobic exercise, cutting back on salt, following the DASH diet, losing weight, quitting smoking, and drinking alcohol in moderation are advised for everyone with high blood pressure or wide pulse pressure along with other heart risks. These changes help lower blood pressure and also reduce stress levels ^[7,18].

Pharmacological Considerations: The decision to start pharmacotherapy in WCH patients remains individualized and controversial. The 2023 ESH Guidelines usually suggest not starting blood pressure medication in WCH patients who have a low risk of heart problems, but they stress the importance of regular check-ups, making lifestyle changes, and using periodic ABPM to track any development of long-term high blood pressure ^[7]. When treatment begins, beta-blockers may be especially helpful in anxiety-related WCH by reducing adrenergic responses, although they are not typically recommended as first-line antihypertensive in current guidelines ^[7,18]. For patients with WCH who also have anxiety disorders or major depression, using medicines for anxiety or depression might help lower blood pressure on their own. This is because these medicines can reduce over activity in the nervous system, balance cortisol levels, and improve how well they follow treatment for other heart-related issues ^[39]. The use of adjunctive antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), in hypertensive patients with comorbid depression has been linked to improved blood pressure control in some studies, although the evidence is inconsistent and individualized clinical judgment is necessary^[47].

Research Gaps and Future Directions

Even though there have been big progress in knowing the brain and body connections related to WCH, there are still some key areas that aren't well understood. The specific connection between trait anxiety and WCH, rather than general blood pressure changes or a tendency toward high blood pressure, needs more clear understanding through long-term studies that use consistent methods to measure anxiety. Depression's role in specifically affecting the white coat effect, rather than long-term high blood pressure, has not been studied much and needs more focused research. The effectiveness of care models that combine blood pressure treatment with proven mental health treatments has not been thoroughly studied in randomized controlled trials specifically focused on WCH. Future research should look into whether treating both anxiety and depression along with chronic health conditions can lower the chance of developing long-term high blood pressure, reduce the number of heart-related problems, and enhance the overall quality of life for these patients. More research is needed to understand how factors like biological sex, ethnicity, socioeconomic status, and digital health tools affect how common WCH is and how it is treated.

CONCLUSION

White coat hypertension is a common and important condition that happens when a person's blood pressure rises during a medical check-up due to the mix of mental and physical factors involved in having their blood pressure measured. Anxiety, whether it is a temporary feeling or a long-term pattern, is the most commonly found psychological factor that affects WCH. It works by increasing activity in the sympathetic nervous system, releasing stress hormones like catecholamine, and making the body more sensitive to changes in the medical setting. Long-term stress can make these problems worse by messing up the body's stress response system. Depression can also lead to heart issues and other cardiovascular problems because it affects the body's inflammation, body control, and behaviour in harmful ways. Getting an accurate diagnosis of WCH through ABPM or HBPM is important to avoid giving unnecessary blood pressure medicine and to find out which patients really need treatment. A full check that combines mental health evaluation with standard tests for heart disease risk should be the usual way doctors handle patient care. Managing WCH requires a personalized approach that considers the whole person — not just high blood pressure, but also the anxiety, stress, and depression that contribute to the condition. Including mental health care in the treatment plan for hypertension can greatly improve blood pressure results and enhance the overall well-being of patients with WCH.

REFERENCES

1. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA. 1988 Jan 8;259(2):225-8. PMID: 3336140.
2. Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol. 2011 Aug 9;8(12):686-93. doi: 10.1038/nrcardio.2011.115. PMID: 21826071.
3. Xu D, Qiu H, Li Z, Yan P, Xu H, Gu Y, Lin H. The Influence of Factors such as Anxiety on the White Coat Effect during the Treatment of Patients with Hypertension. Rev Cardiovasc Med. 2022 Oct 25;23(11):359. doi: 10.31083/j.rcm2311359. PMID: 39076195; PMCID: PMC11269055.
4. Franklin SS, Thijs L, Hansen TW, O'Brien E, Staessen JA. White-coat hypertension: new insights from recent studies. Hypertension. 2013 Dec;62(6):982-7. doi: 10.1161/HYPERTENSIONAHA.113.01275. Epub 2013 Sep 16. PMID: 24041952.
5. Celis H, Fagard RH. White-coat hypertension: a clinical review. Eur J Intern Med. 2004 Oct;15(6):348-357. doi: 10.1016/j.ejim.2004.08.001. PMID: 15522568.
6. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelakovi? B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. Epub 2023 Sep 26. Erratum in: J Hypertens. 2024 Jan 1;42(1):194. doi: 10.1097/HJH.0000000000003621. PMID: 37345492.
7. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019 Feb 1;40(5):475. doi: 10.1093/eurheartj/ehy686. PMID: 30165516.
8. Cohen JB, Lotito MJ, Trivedi UK, Denker MG, Cohen DL, Townsend RR. Cardiovascular Events and Mortality in White Coat Hypertension: A Systematic Review and Meta-analysis. Ann Intern Med. 2019 Jun 18;170(12):853-862. doi: 10.7326/M19-0223. Epub 2019 Jun 11. PMID: 31181575; PMCID: PMC6736754.
9. Mancia G, Bombelli M, Cuspidi C, Facchetti R, Grassi G. Cardiovascular Risk Associated With White-Coat Hypertension: Pro Side of the Argument. Hypertension. 2017 Oct;70(4):668-675. doi: 10.1161/HYPERTENSIONAHA.117.08903. Epub 2017 Aug 28. PMID: 28847891.
10. Cobos B, Haskard-Zolnierek K, Howard K. White coat hypertension: improving the patient-health care practitioner relationship. Psychol Res Behav Manag. 2015 May 2;8:133-41. doi: 10.2147/PRBM.S61192. PMID: 25999772; PMCID: PMC4427265.
11. Ogedegbe G, Pickering TG, Clemow L, Chaplin W, Spruill TM, Albanese GM, Eguchi K, Burg M, Gerin W. The misdiagnosis of hypertension: the role of patient anxiety. Arch Intern Med. 2008 Dec 8;168(22):2459-65. doi: 10.1001/archinte.168.22.2459. PMID: 19064830; PMCID: PMC4843804.
12. Bloomfield DA, Park A. Decoding white coat hypertension. World J Clin Cases. 2017 Mar 16;5(3):82-92. doi: 10.12998/wjcc.v5.i3.82. PMID: 28352632; PMCID: PMC5352963.
13. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013 Jul;34(28):2159-219. doi: 10.1093/eurheartj/eht151. Epub 2013 Jun 14. PMID: 23771844.
14. Pioli MR, Ritter AM, de Faria AP, Modolo R. White coat syndrome and its variations: differences and clinical impact. Integr Blood Press Control. 2018 Nov 8;11:73-79. doi: 10.2147/IBPC.S152761. PMID: 30519088; PMCID: PMC6233698.
15. Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014 Jul;32(7):1359-66. doi: 10.1097/HJH.0000000000000221. PMID: 24886823.
16. Lee EM. When and how to use ambulatory blood pressure monitoring and home blood pressure monitoring for managing hypertension. Clin Hypertens. 2024 Apr 1;30(1):10. doi: 10.1186/s40885-024-00265-w. PMID: 38556887; PMCID: PMC10983625.
17. Kim BK, Rhee MY. Impact of 2018 ESC/ESH and 2017 ACC/AHA Hypertension Guidelines: Difference in Prevalence of White-Coat and Masked Hypertension. Healthcare (Basel). 2020 May 3;8(2):122. doi: 10.3390/healthcare8020122. PMID: 32375221; PMCID: PMC7348809.
18. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13. Erratum in: Hypertension. 2018 Jun;71(6):e140-e144. doi: 10.1161/HYP.0000000000000076. PMID: 29133356.
19. McCarthy CP, Bruno RM, Rahimi K, Touyz RM, McEvoy JW. What Is New and Different in the 2024 European Society of Cardiology Guidelines for the Management of Elevated Blood Pressure and Hypertension? Hypertension. 2025 Mar;82(3):432-444. doi: 10.1161/HYPERTENSIONAHA.124.24173. Epub 2024 Dec 31. PMID: 39970254; PMCID: PMC12011322.
20. Spruill TM, Pickering TG, Schwartz JE, Mostofsky E, Ogedegbe G, Clemow L, Gerin W. The impact of perceived hypertension status on anxiety and the white coat effect. Ann Behav Med. 2007 Aug;34(1):1-9. doi: 10.1007/BF02879915. PMID: 17688391.
21. Siegel WC, Blumenthal JA, Divine GW. Physiological, psychological, and behavioral factors and white coat hypertension. Hypertension. 1990 Aug;16(2):140-6. doi: 10.1161/01.hyp.16.2.140. PMID: 2379947.
22. Grassi G, Turri C, Vailati S, Dell'Oro R, Mancia G. Muscle and skin sympathetic nerve traffic during the "white-coat" effect. Circulation. 1999 Jul 20;100(3):222-5. doi: 10.1161/01.cir.100.3.222. PMID: 10411843.
23. Mancia G, Facchetti R, Bombelli M, Cuspidi C, Grassi G. White-Coat Hypertension: Pathophysiological and Clinical Aspects: Excellence Award for Hypertension Research 2020. Hypertension. 2021 Dec;78(6):1677-1688. doi: 10.1161/HYPERTENSIONAHA.121.16489. Epub 2021 Nov 10. PMID: 34757765; PMCID: PMC9634724.
24. Neumann SA, Jennings JR, Muldoon MF, Manuck SB. White-coat hypertension and autonomic nervous system dysregulation. Am J Hypertens. 2005 May;18(5 Pt 1):584-8. doi: 10.1016/j.amjhyper.2004.11.034. PMID: 15882538.
25. Güler Y, Genç Ö, Y?ld?r?m A, Halil US, Çapar G, Özdo?an CG, Erdo?an A, Güler A, K?rma C. A Metric Shedding Light on the Relationship Between White Coat Hypertension and Anxiety: The Hospital Anxiety and Depression Scale-Anxiety. Anatol J Cardiol. 2024 Oct 30;29(1):2-10. doi: 10.14744/AnatolJCardiol.2024.4746. PMID: 39475171; PMCID: PMC11694686.
26. Guler Y, Genc O, Yildirim A, Erdogan A, Akgun H, Acar G, Guler A, Kirma C. Templer's death anxiety scale on the relationship between white coat hypertension and anxiety: A cross-sectional study. J Hum Hypertens. 2024 Jul;38(7):561-567. doi: 10.1038/s41371-024-00920-7. Epub 2024 Jun 6. PMID: 38844549.
27. Lantelme P, Milon H, Gharib C, Gayet C, Fortrat JO. White coat effect and reactivity to stress: cardiovascular and autonomic nervous system responses. Hypertension. 1998 Apr;31(4):1021-9. doi: 10.1161/01.hyp.31.4.1021. PMID: 9535430.
28. Terracciano A, Scuteri A, Strait J, Sutin AR, Meirelles O, Marongiu M, Orru M, Pilia MG, Ferrucci L, Cucca F, Schlessinger D, Lakatta E. Are personality traits associated with white-coat and masked hypertension? J Hypertens. 2014 Oct;32(10):1987-92; discussion 1992. doi: 10.1097/HJH.0000000000000289. PMID: 25186529; PMCID: PMC4196211.
29. Särnholm J, Kronish IM. Psychological Distress and Hypertension Diagnostic Testing: Is There Anything to Worry About? Am J Hypertens. 2024 Jan 1;37(1):18-20. doi: 10.1093/ajh/hpad096. PMID: 37798140; PMCID: PMC10724523.
30. Hamam MS, Kunjummen E, Hussain MS, Nasereldin M, Bennett S, Miller J. Anxiety, Depression, and Pain: Considerations in the Treatment of Patients with Uncontrolled Hypertension. Curr Hypertens Rep. 2020 Nov 10;22(12):106. doi: 10.1007/s11906-020-01117-2. PMID: 33170388.
31. Sparrenberger F, Cichelero FT, Ascoli AM, Fonseca FP, Weiss G, Berwanger O, Fuchs SC, Moreira LB, Fuchs FD. Does psychosocial stress cause hypertension? A systematic review of observational studies. J Hum Hypertens. 2009 Jan;23(1):12-9. doi: 10.1038/jhh.2008.74. Epub 2008 Jul 10. PMID: 18615099.
32. Lantelme P, Milon H, Gharib C, Gayet C, Fortrat JO. White coat effect and reactivity to stress: cardiovascular and autonomic nervous system responses. Hypertension. 1998 Apr;31(4):1021-9. doi: 10.1161/01.hyp.31.4.1021. PMID: 9535430.
33. Humbert X, Fedrizzi S, Alexandre J, Menotti A, Manrique A, Laurenzi M, Touzé E, Puddu PE. Impact of Sex on Office White Coat Effect Tail: Investigating Two Italian Residential Cohorts. Sci Rep. 2019 Nov 21;9(1):17237. doi: 10.1038/s41598-019-53109-1. PMID: 31754227; PMCID: PMC6872870.
34. Spruill TM. Chronic psychosocial stress and hypertension. Curr Hypertens Rep. 2010 Feb;12(1):10-6. doi: 10.1007/s11906-009-0084-8. PMID: 20425153; PMCID: PMC3694268.
35. Johnson HM. Anxiety and Hypertension: Is There a Link? A Literature Review of the Comorbidity Relationship Between Anxiety and Hypertension. Curr Hypertens Rep. 2019 Jul 18;21(9):66. doi: 10.1007/s11906-019-0972-5. PMID: 31321565.
36. Graham N, Smith DJ. Comorbidity of depression and anxiety disorders in patients with hypertension. J Hypertens. 2016 Mar;34(3):397-8. doi: 10.1097/HJH.0000000000000850. PMID: 26818922.
37. Satapathy P, Gaidhane AM, Vadia N, Menon SV, Chennakesavulu K, Panigrahi R, Bushi G, Singh M, Sah S, Turkar A, Rao SG, Goh KW, Shabil M, Mawejje E. Between Depression and Risk of Hypertension: A Systematic Review and Meta-Analysis. Brain Behav. 2025 Sep;15(9):e70931. doi: 10.1002/brb3.70931. Erratum in: Brain Behav. 2025 Oct;15(10):e71009. doi: 10.1002/brb3.71009. PMID: 40999622; PMCID: PMC12463727.
38. Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013 Sep;18(9):963-74. doi: 10.1038/mp.2013.20. Epub 2013 Feb 26. PMID: 23439482; PMCID: PMC3674224.
39. Akangbe BO, Akinwumi FE, Adekunle DO, Tijani AA, Aneke OB, Anukam S. Comorbidity of Anxiety and Depression With Hypertension Among Young Adults in the United States: A Systematic Review of Bidirectional Associations and Implications for Blood Pressure Control. Cureus. 2025 Jul 22;17(7):e88532. doi: 10.7759/cureus.88532. PMID: 40851703; PMCID: PMC12370160.
40. Muneta S, Kobayashi T, Matsumoto I. Personality characteristics of patients with "white coat" hypertension. Hypertens Res. 1997 Jun;20(2):99-104. doi: 10.1291/hypres.20.99. PMID: 9220273.
41. Di Tella M, Benfante A, Airale L, Castelli L, Milan A. Alexithymia and Hypertension: Does Personality Matter? A Systematic Review and Meta-analysis. Curr Cardiol Rep. 2023 Jul;25(7):711-724. doi: 10.1007/s11886-023-01894-7. Epub 2023 May 22. PMID: 37212924; PMCID: PMC10307708.
42. Dolan E, Stanton A, Atkins N, Den Hond E, Thijs L, McCormack P, Staessen J, O'Brien E. Determinants of white-coat hypertension. Blood Press Monit. 2004 Dec;9(6):307-9. doi: 10.1097/00126097-200412000-00007. PMID: 15564985.
43. Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016 Apr;34(4):593-9. doi: 10.1097/HJH.0000000000000832. PMID: 26734955.
44. Sipahioglu NT, Sipahioglu F. Closer look at white-coat hypertension. World J Methodol. 2014 Sep 26;4(3):144-50. doi: 10.5662/wjm.v4.i3.144. PMID: 25332913; PMCID: PMC4202453.
45. Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, Freedland KE, Jaffe AS, Leifheit-Limson EC, Sheps DS, Vaccarino V, Wulsin L; American Heart Association Statistics Committee of the Council on Epidemiology and Prevention and the Council on Cardiovascular and Stroke Nursing. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014 Mar 25;129(12):1350-69. doi: 10.1161/CIR.0000000000000019. Epub 2014 Feb 24. PMID: 24566200.
46. Shah RM, Doshi S, Shah S, Patel S, Li A, Diamond JA. Impacts of Anxiety and Depression on Clinical Hypertension in Low-Income US Adults. High Blood Press Cardiovasc Prev. 2023 Jul;30(4):337-342. doi: 10.1007/s40292-023-00584-3. Epub 2023 Jun 1. PMID: 37261618; PMCID: PMC10233551.
47. Grippo AJ, Johnson AK. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress. 2009 Jan;12(1):1-21. doi: 10.1080/10253890802046281. PMID: 19116888; PMCID: PMC2613299.
48. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens. 2011 Jan;24(1):52-8. doi: 10.1038/ajh.2010.203. Epub 2010 Sep 16. PMID: 20847724.
49. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006 May;47(5):846-53. doi: 10.1161/01.HYP.0000215363.69793.bb. Epub 2006 Mar 27. PMID: 16567588.
50. Stergiou GS, Asayama K, Thijs L, Kollias A, Niiranen TJ, Hozawa A, Boggia J, Johansson JK, Ohkubo T, Tsuji I, Jula AM, Imai Y, Staessen JA; International Database on HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO) Investigators. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension. 2014 Apr;63(4):675-82. doi: 10.1161/HYPERTENSIONAHA.113.02741. Epub 2014 Jan 13. PMID: 24420553.